PSI Names Dr. Gabriele Schmoetzer, Head of Regulatory Affairs Germany

ZUG, Switzerland--(BUSINESS WIRE)--PSI CRO, a full-service contract research organization, announced today the appointment of Dr. Gabriele Schmoetzer as Head of Regulatory Affairs, Germany. Dr. Schmoetzer will be supervising regulatory-related activities for Germany, Austria and Switzerland.

Dr. Schmoetzer holds a PhD in nutritional science and brings 24 years of clinical research experience to PSI, having worked for small, mid-size and large CROs. In her career, Dr. Schmoetzer has held positions in international and global project management, with a subsequent switch to the Regulatory Affairs area, where she has been involved actively in managerial positions.

Dr. Schmoetzer has been responsible for clinical trial submissions in the German-speaking region of Europe and in a number of other EU countries, too. Throughout her career, Dr. Schmoetzer has been exposed to numerous RA-specific processes so she brings to PSI both technical expertise and profound knowledge of the Clinical Trial regulatory environment.

About PSI CRO AG: PSI is a privately-held, full-service contract research organization (CRO), operating globally. PSI's reputation on the market place is that of a no-nonsense CRO, capable of saving pharmaceutical sponsors millions of development dollars by consistently meeting clinical trial timelines. PSI's global reach supports the operations of clinical trials across multiple countries and continents. PSI is known to be highly selective about the work it pursues. PSI has exceptionally high repeat and referral business rates, while maintaining minimal staff turnover, indicative of its commitment to be the best CRO in the world as measured by its customers and employees. Global headquarters are located in Zug (Zürich), Switzerland at 113a Baarerstrasse 6300. www.psi-cro.com

Contacts

PSI CRO AG
Barbara Breen, +1 847-202-1120
[email protected]

Suggested Articles

Astellas will develop Frequency's hearing loss drug outside the U.S. in exchange for $80 million upfront and the promise of $545 million down the line.

Inovio Pharmaceuticals is cutting 28% of its workforce and swinging the ax to a bladder cancer test.

The agency was less likely to go against a recommendation when the panellists were united in their opinion.